Belite Bio (BLTE) vs Liquidia (LQDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Liquidia (LQDA) has outperformed Belite Bio (BLTE) over the past year, gaining 87.0% versus a gain of 5.7%. Belite Bio is the larger company by market cap ($5.17 billion vs $4.90 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | LQDA |
|---|---|---|
| Share price | $127.38 | $54.43 |
| Market cap | $5.17B | $4.90B |
| 1-day change | -15.65% | -3.88% |
| YTD return | -20.37% | +57.81% |
| 1-year return | +5.66% | +86.98% |
| 5-year return | — | +1224.33% |
| Forward P/E | — | 15.12 |
| EPS (TTM) | $-2.84 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $158.32M |
| Revenue growth (YoY) | — | +1031.18% |
| Net income (latest FY) | $-77.61M | $-68.92M |
| Operating margin | — | -32.45% |
| Net margin | — | -43.53% |
| 52-week high | $200.00 | $93.61 |
| 52-week low | $115.41 | $22.31 |
| Distance from 52-week high | -36.31% | -41.85% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +82.92% | +21.50% |
| Average volume | 195.65K | 3.52M |
| Shares outstanding | 40.61M | 90.11M |
| Employees | 41 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LQDA has outperformed BLTE by 81.3 percentage points over the past year.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
BLTE vs LQDA FAQ
Which is bigger, Belite Bio or Liquidia?
Belite Bio (BLTE) is larger, with a market capitalization of $5.17B compared with $4.90B for Liquidia (LQDA).
Which stock has performed better over the past year, BLTE or LQDA?
LQDA returned +86.98% over the past 12 months, compared with +5.66% for BLTE (price return, excluding dividends). Past performance does not predict future results.
Are Belite Bio and Liquidia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.